Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000520 | 0.85 | HTR7 (0.50) | NR4A2KDM4EALDH1A1HTR7 | |
| SCHEMBL4137522 | 0.81 | NR4A2 (0.66) | NR4A2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL440604 | 0.81 | NR4A2 (0.66) | NR4A2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL17782448 | 0.81 | NR4A2 (0.70) | NR4A2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL2001794 | 0.78 | SMN1; SMN2 (0.47) | KMT2AMEN1KDM4ETHRBGAA | |
| SCHEMBL6298233 | 0.78 | NR4A2 (0.61) | NR4A2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL408819 | 0.77 | NR4A2 (1.00) | NR4A2KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL2002753 | 0.77 | MAOB (0.47) | ALDH1A1THRBSMN1; SMN2MAPT | |
| SCHEMBL2001384 | 0.76 | CFTR (0.45) | SMN1; SMN2HTR7 | |
| SCHEMBL19407224 | 0.76 | NR4A2 (0.79) | NR4A2KMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960569-B2 | Such as 3-(2-isopropylphenyl)-N-phenyl-1H-indol-1-carboxamide; purinergic receptors (P2Y1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2077992-A2 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080221197-A1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-11 | — | — | US | disclosed |
| WO-2008048981-A2 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221197-A1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | NR4A2 1759/4885KMT2A 4043/4885MEN1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.